Q1 sales orders in line to achieve or exceed initial annual projections.
Vancouver, BC / April 7, 2021 / BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) announced today that sales orders of VINIA® in Q1/2021 reached an all-time high of US$ 377,756, representing a 17% increase over Q4/2020 sales orders, and a 668% increase over Q1/2020. The total number of VINIA® purchase orders in Q1/2021 also reached a new high of 2,190, an increase of 45% versus Q4/2020.
The results in the Israeli market, with a relatively small population of 9 million, are in line with achieving or exceeding the higher end of the US$ 1.4- 1.5 million guidance range given on March 23rd, 2021 for 2021 projected sales orders in Israel.
The company cites that the average dollar purchase amount for first-time customers is US$ 169, which far exceeds the cost of acquisition of these customers, resulting in the healthy unit economics required to deliver a profitable Direct-to-Consumer business. The consistent traction achieved by VINIA® highlights the recognition by the Israeli consumer of the quality and efficacy of VINIA®, resulting from its leadership position of being the only dietary supplement product containing piceid resveratrol from red grapes with high levels of solubility and bioavailability.
The accumulated knowledge and experience from the launch of VINIA® in the Israeli market will benefit the Company’s imminent launch of VINIA® in the US market. The BioHarvest marketing team is leveraging this experience to optimize the consumer messaging and the customer acquisition process to achieve a successful launch in the US market. As part of that e-commerce launch, BioHarvest plans to make a significant investment to establish the VINIA® brand and to communicate its unique properties.
“I am proud of the Company’s achievements in the last quarter”, said Ilan Sobel, CEO of BioHarvest, and added “I made a commitment to all BioHarvest stakeholders to build a professional team and bring “Best in Class” talents to support all the facets of a fully operational company. The sales results of Q1 are a testimony to their talent, which has allowed the Company to grow from an R&D organization into one that has all the elements needed to bring highly differentiated wellness products to the end consumer. I look forward to the Company continuing its momentum in Israel during Q2 and beyond and to disrupting the US market shortly, with the launch of VINIA® in that region.”
The company reminds shareholders that the Q1, 2021 BioHarvest Sciences Shareholder Update is April 8, 2PM EST / 11AM PST. All shareholders, media, and interested investors are welcome to join. All registrants will be emailed a recording of the session.
About BioHarvest Sciences Inc.
Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.’s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.